Amendment to Paid-in Capital Increase Details
젬백스
082270
Signal Score
Historical Avg Return (5d)
+0.22%
Data Coverage
100%n=2507
Risk-adjusted indicator based on 2507 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Previous Total Shares Outstanding: 44,185,583 Shares
- • Amended Total Shares Outstanding: 44,269,203 Shares
- • New Shares Subscription Date: December 24, 2025
- • New Shares Payment Date: August 21, 2026
AI Analysis Summary
GemVax & KAEL Co.,Ltd. filed an amendment to its Material Fact Report regarding a paid-in capital increase. The primary change is an adjustment to the total number of common shares outstanding from 44,185,583 to 44,269,203 shares, due to a change in the payment date. The new shares subscription date remains December 24, 2025, while the payment date has been updated to August 21, 2026. The purpose of the capital increase is for R&D investment, specifically for clinical trial expenses for progressive supranuclear palsy (PSP). The amendment itself is a procedural update, indicating no immediate new financial impact beyond the previously announced capital increase.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.